HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuji Matsuzawa Selected Research

Nicotinic Acids

1/2020Pemafibrate, a New Selective PPARĪ± Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuji Matsuzawa Research Topics

Disease

55Obesity
01/2021 - 04/2002
36Insulin Resistance
01/2021 - 02/2002
31Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 02/2002
28Type 2 Diabetes Mellitus (MODY)
01/2020 - 07/2002
26Coronary Artery Disease (Coronary Atherosclerosis)
06/2022 - 02/2002
23Atherosclerosis
10/2016 - 09/2002
21Hypertension (High Blood Pressure)
02/2021 - 11/2002
19Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 07/2002
17Hypercholesterolemia
10/2015 - 01/2002
15Hypoadiponectinemia
05/2012 - 09/2002
14Vascular Diseases (Vascular Disease)
04/2008 - 04/2002
13Coronary Disease (Coronary Heart Disease)
02/2021 - 11/2002
13Neoplasms (Cancer)
01/2010 - 04/2002
12Diabetes Mellitus
01/2010 - 11/2002
11Body Weight (Weight, Body)
08/2010 - 10/2002
10Inflammation (Inflammations)
11/2016 - 06/2003
9Abdominal Obesity
03/2013 - 01/2003
8Dyslipidemias (Dyslipidemia)
02/2021 - 01/2003
6Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
02/2021 - 01/2004
6Hyperglycemia
10/2015 - 01/2002
6Hyperuricemia
06/2011 - 06/2011
5Hypertriglyceridemia
01/2020 - 07/2003
5Cholesteryl Ester Transfer Protein Deficiency
10/2016 - 07/2002
5Gout
06/2011 - 06/2011
4Xanthomatosis (Xanthoma)
02/2021 - 08/2015
4Stroke (Strokes)
06/2020 - 11/2005
4Mason-Type Diabetes
12/2005 - 01/2002
4Glucose Intolerance
01/2005 - 06/2002
4Lipodystrophy
06/2004 - 05/2002
3Liver Diseases (Liver Disease)
01/2020 - 10/2007
3Cushing Syndrome
01/2016 - 10/2003
3Non-alcoholic Fatty Liver Disease
10/2015 - 10/2007
3Fatty Liver
10/2015 - 02/2002
3Drug-Related Side Effects and Adverse Reactions
06/2011 - 06/2011
3Hyperlipidemias (Hyperlipidemia)
10/2006 - 06/2003
3Vascular Remodeling
02/2006 - 06/2002
3Overweight
12/2005 - 11/2002
3Chronic Kidney Failure (Chronic Renal Failure)
01/2005 - 01/2002
3Hyperinsulinism (Hyperinsulinemia)
11/2002 - 10/2002
2Chronic Renal Insufficiency
06/2020 - 05/2003
2Kidney Diseases (Kidney Disease)
06/2020 - 06/2012
2Metabolic Diseases (Metabolic Disease)
01/2020 - 05/2019
2Necrosis
07/2019 - 12/2005
2Tangier Disease
10/2018 - 08/2002
2Weight Gain
10/2015 - 10/2002
2Gastritis
08/2011 - 12/2003

Drug/Important Bio-Agent (IBA)

95AdiponectinIBA
01/2021 - 01/2002
28LipidsIBA
02/2021 - 10/2002
26AdipokinesIBA
01/2021 - 04/2002
25Glucose (Dextrose)FDA LinkGeneric
10/2020 - 01/2002
22HDL CholesterolIBA
02/2021 - 07/2002
19CholesterolIBA
11/2018 - 07/2002
19Proteins (Proteins, Gene)FDA Link
08/2012 - 04/2002
17Insulin (Novolin)FDA Link
10/2020 - 06/2002
17Triglycerides (Triacylglycerol)IBA
01/2016 - 11/2002
12Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2020 - 01/2002
11oxidized low density lipoproteinIBA
02/2021 - 10/2002
9LDL CholesterolIBA
02/2021 - 01/2004
9Simvastatin (Zocor)FDA LinkGeneric
03/2010 - 12/2002
8Messenger RNA (mRNA)IBA
04/2013 - 04/2002
8Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2007 - 04/2002
7Probucol (Lorelco)FDA Link
06/2022 - 12/2008
7Eicosapentaenoic AcidIBA
01/2012 - 07/2008
7C-Reactive ProteinIBA
08/2011 - 02/2003
7Epidermal Growth Factor (EGF)IBA
01/2007 - 01/2002
6HDL LipoproteinsIBA
02/2021 - 08/2002
6Pharmaceutical PreparationsIBA
01/2020 - 11/2003
6Heparin (Liquaemin)FDA LinkGeneric
01/2007 - 04/2002
6Nicotinamide PhosphoribosyltransferaseIBA
01/2007 - 01/2005
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2007 - 07/2002
6Hormones (Hormone)IBA
05/2005 - 05/2002
5Cholesterol Ester Transfer ProteinsIBA
10/2016 - 07/2002
5FebuxostatFDA Link
06/2011 - 06/2011
5Xanthine OxidaseIBA
06/2011 - 06/2011
5Uric Acid (Urate)IBA
06/2011 - 11/2002
5Plasminogen InactivatorsIBA
01/2007 - 05/2004
5ApolipoproteinsIBA
04/2005 - 02/2002
5Lipoproteins (Lipoprotein)IBA
03/2005 - 05/2003
4LDL Lipoproteins (beta Lipoproteins)IBA
02/2021 - 01/2004
4Allopurinol (Remid)FDA LinkGeneric
06/2011 - 06/2011
4purineIBA
06/2011 - 06/2011
4LeptinIBA
01/2011 - 05/2002
3AntioxidantsIBA
02/2021 - 12/2008
3Fibric Acids (Fibrates)IBA
01/2020 - 08/2003
3lipoprotein cholesterolIBA
06/2012 - 05/2005
3Hemoglobins (Hemoglobin)IBA
06/2011 - 01/2008
3Hypoglycemic Agents (Hypoglycemics)IBA
01/2007 - 04/2004
3Plasminogen Activator Inhibitor 1IBA
12/2005 - 05/2004
3PPAR gammaIBA
05/2005 - 02/2002
3Hepatocyte Nuclear FactorsIBA
04/2005 - 01/2002
3Interleukin-6 (Interleukin 6)IBA
12/2003 - 01/2003
2CreatinineIBA
01/2020 - 08/2010
2(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
01/2020 - 05/2019
2Lipoprotein Lipase (Diacylglycerol Lipase)IBA
01/2013 - 08/2003
2AcidsIBA
12/2011 - 12/2003
2Brain-Derived Neurotrophic Factor (BDNF)IBA
09/2011 - 12/2009
2CytokinesIBA
08/2011 - 01/2003

Therapy/Procedure

16Therapeutics
02/2021 - 12/2002
7Secondary Prevention
02/2021 - 12/2002
3Highly Active Antiretroviral Therapy (HAART)
06/2004 - 04/2003